While under competitive pressure from Novartis and Eli Lilly, Pfizer can tally up a unique trial win for its Ibrance in a ...

The benefit of the PARP inhibitor in patients with germline BRCA pathogenic variants remains evident 10 years after the first ...

Meta-analysis of three trials found that immediate breast surgery in women over 70 cut breast cancer death rates in half ...

The Institute of Cancer Research believes that animal research is essential to understand how cancers develop within a whole organism, and how to treat it.

The findings from the study demonstrated a substantial decrease in reoperation rates when the Histolog scanner was utilised.

AstraZeneca and MSD's PARP inhibitor Lynparza has improved long-term survival when given as adjuvant therapy for early breast ...

The European Medicines Agency (EMA) will allow Novo Nordisk to add risk reduction for events related to kidney disease to the label of its diabetes drug Ozempic, the Danish drugmaker said in a ...

Biovica signed an agreement with US Biotech company in clinical phase Biovica received a significant order for TKa testing services Biovica published the outcome of exercise of warrants from series ...

Receiving immediate surgery was associated with a reduction in local recurrence of breast cancer in elderly patients versus delaying surgery.

Avril Mathie - who has clocked up a record of 8-1-1 since switching to the fight game after winning the Miss Swimsuit USA crown - believes the cosmetic procedure will pay off in the ring.

SamanTree Medical, a leader in oncologic surgical imaging innovation, today announced promising results from the SHIELD study ...

Adjuvant Lynparza remains beneficial for patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer, study results have shown.